ReviewInternational journal of hematology2013
Current approaches for the treatment of multiple myeloma.
Review in International journal of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.International journal of hematology · 2015Trial
- Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.International journal of hematology · 2013Trial
- Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects.Cancer drug resistance (Alhambra, Calif.) · 2024Article
- Review
- A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.Virchows Archiv : an international journal of pathology · 2020Review
- Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.Journal of clinical and experimental hematopathology : JCEH · 2016Review
- Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma.International journal of hematology · 2015Article
- Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.International journal of hematology · 2015Article
- Gastric invasion of multiple myeloma presenting as gastrointestinal bleeding.International journal of hematology · 2015Article
- Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.International journal of hematology · 2015Article
- Current treatment landscape for relapsed and/or refractory multiple myeloma.Nature reviews. Clinical oncology · 2015Review
- Ikaros fingers on lymphocyte differentiation.International journal of hematology · 2014Review
- Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.International journal of hematology · 2014Article
- Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study.International journal of hematology · 2014Article
- Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.International journal of hematology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of novel therapeutic agents over the past decade, including the proteasome inhibitor, bortezomib, and the immunomodulatory drugs, lenalidomide and thalidomide, has resulted in improved outcomes for patients with multiple myeloma. However, there is still considerable controversy as to which regimen should be used as first-line therapy, which patients should be considered for autologous or allogeneic transplantation, and how consolidation or maintenance therapy is used in patients that have a good response to first-line therapy. The present paper will review clinical evidence from previous and ongoing studies to explore issues related to these questions.
Indexed as
Identifiers
23475758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.